HomeHealthcare & Life Sciences Primary Sclerosing Cholangitis Market

Primary Sclerosing Cholangitis Market Size, Share & Demand Report By Therapy Type (Novel Biologics, Symptomatic & Supportive Treatment), By End-Use (Hospitals & Specialty Clinics, Research & Diagnostic Centers), By Patient Age Group (Pediatric, Adult, Geriatric), By Region & Segment Forecasts, 2025–2033

Starting From
USD 3950

Buy Now

Report Benefits

Develop business strategies by understanding the trends shaping and driving the Market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track sales in the global and country-specific Market.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Executive Summary
1. Introduction
Market Introduction
1. Market Definition
2. Scope of the Study
3. Market Structure
Research Methodology
1. Primary Research
2. Research Methodology
3. Assumptions & Exclusions
4. Secondary Data Sources
Market Factor Analysis
1. Value Chain Analysis: Primary Sclerosing Cholangitis Market
2. Porters Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitution
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Dynamics
1. Drivers
2. Restraints
3. Opportunities
Recent Trends Analysis
Impact of COVID-19 on Primary Sclerosing Cholangitis Market
1. Pre and Post Covid -19 Market Scenario Analysis
2. Market Recovery Timeline and Challenge
3. Measures Taken by Top Players
Regulatory Landscape
Primary Sclerosing Cholangitis Market, By Drug Class
1. Introduction
  1. Market Size and Forecast, By Drug Class
2. Ursodeoxycholic Acid (UDCA)
  1. Market Size and Forecast, By Region
3. FXR Agonists
  1. Market Size and Forecast, By Region
4. Immunosuppressants
  1. Market Size and Forecast, By Region
5. Others
  1. Market Size and Forecast, By Region
Primary Sclerosing Cholangitis Market, By Treatment Type
1. Introduction
  1. Market Size and Forecast, By Treatment Type
2. Drug Therapy
  1. Market Size and Forecast, By Region
3. Biologic Therapy
  1. Market Size and Forecast, By Region
4. Liver Transplantation
  1. Market Size and Forecast, By Region
Primary Sclerosing Cholangitis Market, By End User
1. Introduction
  1. Market Size and Forecast, By End User
2. Hospitals
  1. Market Size and Forecast, By Region
3. Specialty Clinics
  1. Market Size and Forecast, By Region
4. Research Institutes
  1. Market Size and Forecast, By Region
Regional Overview
1. Introduction
  1. Market Size and Forecast
2. North America
  1. Market Size and Forecast
    1. By Drug Class
      1. Ursodeoxycholic Acid (UDCA)
      2. FXR Agonists
      3. Immunosuppressants
      4. Others
    2. By Treatment Type
      1. Drug Therapy
      2. Biologic Therapy
      3. Liver Transplantation
    3. By End User
      1. Hospitals
      2. Specialty Clinics
      3. Research Institutes
  2. U.S.
    1. By Drug Class
      1. Ursodeoxycholic Acid (UDCA)
      2. FXR Agonists
      3. Immunosuppressants
      4. Others
    2. By Treatment Type
      1. Drug Therapy
      2. Biologic Therapy
      3. Liver Transplantation
    3. By End User
      1. Hospitals
      2. Specialty Clinics
      3. Research Institutes
  3. Canada
3. Europe
  1. Market Size and Forecast
    1. By Drug Class
      1. Ursodeoxycholic Acid (UDCA)
      2. FXR Agonists
      3. Immunosuppressants
      4. Others
    2. By Treatment Type
      1. Drug Therapy
      2. Biologic Therapy
      3. Liver Transplantation
    3. By End User
      1. Hospitals
      2. Specialty Clinics
      3. Research Institutes
  2. U.K.
    1. By Drug Class
      1. Ursodeoxycholic Acid (UDCA)
      2. FXR Agonists
      3. Immunosuppressants
      4. Others
    2. By Treatment Type
      1. Drug Therapy
      2. Biologic Therapy
      3. Liver Transplantation
    3. By End User
      1. Hospitals
      2. Specialty Clinics
      3. Research Institutes
  3. Germany
  4. France
  5. Spain
  6. Italy
  7. Russia
  8. Nordic
  9. Benelux
  10. Rest of Europe
4. APAC
  1. Market Size and Forecast
    1. By Drug Class
      1. Ursodeoxycholic Acid (UDCA)
      2. FXR Agonists
      3. Immunosuppressants
      4. Others
    2. By Treatment Type
      1. Drug Therapy
      2. Biologic Therapy
      3. Liver Transplantation
    3. By End User
      1. Hospitals
      2. Specialty Clinics
      3. Research Institutes
  2. China
    1. By Drug Class
      1. Ursodeoxycholic Acid (UDCA)
      2. FXR Agonists
      3. Immunosuppressants
      4. Others
    2. By Treatment Type
      1. Drug Therapy
      2. Biologic Therapy
      3. Liver Transplantation
    3. By End User
      1. Hospitals
      2. Specialty Clinics
      3. Research Institutes
  3. South Korea
  4. Japan
  5. India
  6. Australia
  7. Singapore
  8. Taiwan
  9. South East Asia
  10. Rest of Asia-Pacific
5. Middle East and Africa
  1. Market Size and Forecast
    1. By Drug Class
      1. Ursodeoxycholic Acid (UDCA)
      2. FXR Agonists
      3. Immunosuppressants
      4. Others
    2. By Treatment Type
      1. Drug Therapy
      2. Biologic Therapy
      3. Liver Transplantation
    3. By End User
      1. Hospitals
      2. Specialty Clinics
      3. Research Institutes
  2. UAE
    1. By Drug Class
      1. Ursodeoxycholic Acid (UDCA)
      2. FXR Agonists
      3. Immunosuppressants
      4. Others
    2. By Treatment Type
      1. Drug Therapy
      2. Biologic Therapy
      3. Liver Transplantation
    3. By End User
      1. Hospitals
      2. Specialty Clinics
      3. Research Institutes
  3. Turky
  4. Saudi Arabia
  5. South Africa
  6. Egypt
  7. Nigeria
  8. Rest of MEA
6. LATAM
  1. Market Size and Forecast
    1. By Drug Class
      1. Ursodeoxycholic Acid (UDCA)
      2. FXR Agonists
      3. Immunosuppressants
      4. Others
    2. By Treatment Type
      1. Drug Therapy
      2. Biologic Therapy
      3. Liver Transplantation
    3. By End User
      1. Hospitals
      2. Specialty Clinics
      3. Research Institutes
  2. Brazil
    1. By Drug Class
      1. Ursodeoxycholic Acid (UDCA)
      2. FXR Agonists
      3. Immunosuppressants
      4. Others
    2. By Treatment Type
      1. Drug Therapy
      2. Biologic Therapy
      3. Liver Transplantation
    3. By End User
      1. Hospitals
      2. Specialty Clinics
      3. Research Institutes
  3. Mexico
  4. Argentina
  5. Chile
  6. Colombia
  7. Rest of LATAM
Competitive Landscape, 2025
1. Introduction
2. Primary Sclerosing Cholangitis Market Share Analysis, 2025 (%)
  1. Market Share Analysis, 2025
  2. Competition Ranking, 2025
  3. Key Developments & Growth Strategies
    1. Merger & Acquisition
    2. Product Launch
    3. Expansion
  4. Consolidated SWOT Analysis of Key Players
Company Profile
1. Gilead Sciences, Inc.
  1. Business Overview
  2. Financial Data
  3. Key Product Categories
  4. Recent Developments
2. Intercept Pharmaceuticals, Inc. (Alfasigma Group)
3. AbbVie Inc.
4. Novartis AG
5. Pfizer Inc.
6. Takeda Pharmaceutical Company Limited
7. Bristol Myers Squibb Company
8. Eli Lilly and Company
9. GlaxoSmithKline plc
10. Johnson & Johnson

Report Benefits

Table of Contents